Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Conditions: Metastatic Breast Cancer Interventions: Drug: Eribulin; Drug: Sintilimab Sponsors: Zhejiang Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Hospitals | Research